Clinic
Methodist Healthcare System of San Antonio, LTD., L.L.P.
Methodist Healthcare System of San Antonio, LTD., L.L.P. was paid $68.01M by Medicaid between Mar 2019 and Dec 2024, across 187 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoMETHODIST HEALTHCARE SYSTEM OF SAN ANTONIO, LTD., L.L.P.
SAN ANTONIO, TX 78229
SAN ANTONIO, TX 78229
33aNPI1124074273assigned 05/26/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$68.01M
24GClaims856,650
24DCodes billed187
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#5 of 320
Median peer was paid$205K
This provider vs. median332×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 642 | $27K | |
| 2020 | 19,063 | $1.32M | |
| 2021 | 195,932 | $14.15M | |
| 2022 | 239,480 | $19.44M | |
| 2023 | 243,230 | $20.89M | |
| 2024incomplete | 158,303 | $12.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 166,771 | 163,291 | $31.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 71,045 | 67,736 | $24.34M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.8% | 37,242 | 36,772 | $5.95M |
| 80053 | Comprehensive metabolic panel | 1.0% | 55,307 | 50,680 | $705K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,827 | 3,751 | $550K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 29,349 | 28,922 | $388K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,626 | 1,590 | $288K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,833 | 2,698 | $261K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 32,698 | 32,044 | $259K |
| 85027 | <1% | 80,809 | 71,737 | $229K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,846 | 17,851 | $194K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,990 | 6,140 | $183K |
175 more codes
| 76801 | <1% | 1,583 | $156K | |
| 99285 | Emergency room visit (most serious) | <1% | 2,622 | $146K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,552 | $128K |
| 80076 | <1% | 1,965 | $124K | |
| 76770 | <1% | 663 | $123K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 28,496 | $122K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,504 | $120K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,358 | $115K |
| 71045 | Radiologic examination, chest; single view | <1% | 21,931 | $110K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 387 | $93K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,050 | $89K |
| 83735 | <1% | 11,954 | $88K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,496 | $87K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,295 | $86K |
| 83615 | <1% | 3,495 | $71K | |
| 16020 | <1% | 270 | $69K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 7,282 | $61K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,609 | $60K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,343 | $60K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 331 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,796 | $43K |
| 87507 | <1% | 970 | $38K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 536 | $37K |
| 81001 | <1% | 30,313 | $35K | |
| 93975 | <1% | 139 | $27K | |
| 84702 | <1% | 2,990 | $25K | |
| 82657 | <1% | 711 | $25K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 28 | $25K |
| 93017 | <1% | 335 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 455 | $22K |
| 49083 | <1% | 137 | $20K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,154 | $20K |
| 83880 | <1% | 3,087 | $19K | |
| 83690 | <1% | 10,864 | $18K | |
| 88312 | <1% | 548 | $18K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,287 | $18K |
| 84100 | <1% | 3,217 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,333 | $17K |
| 74018 | <1% | 570 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,882 | $16K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,193 | $15K |
| 93976 | <1% | 176 | $14K | |
| 84484 | <1% | 7,578 | $13K | |
| 74019 | <1% | 2,096 | $13K | |
| G0378 | Hospital observation service, per hour | <1% | 196 | $13K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 214 | $13K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,365 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 331 | $11K |
| 87040 | <1% | 2,996 | $11K | |
| 84703 | <1% | 5,255 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,174 | $10K |
| 97163 | <1% | 146 | $10K | |
| 82248 | <1% | 2,759 | $9K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 152 | $9K |
| 81025 | <1% | 2,806 | $9K | |
| 86140 | <1% | 3,778 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 777 | $8K |
| 86850 | <1% | 1,202 | $8K | |
| 81003 | <1% | 7,847 | $8K | |
| 97166 | <1% | 75 | $7K | |
| 87631 | <1% | 767 | $7K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 197 | $7K |
| 73630 | <1% | 366 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,938 | $5K |
| G0175 | Scheduled interdisciplinary team conference (minimum of three exclusive of patient care nursing staff) with patient present | <1% | 102 | $5K |
| 85610 | <1% | 4,043 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 7,830 | $5K |
| 80197 | <1% | 2,446 | $5K | |
| 85730 | <1% | 2,717 | $5K | |
| 99152 | <1% | 484 | $4K | |
| 86900 | <1% | 2,732 | $4K | |
| 86901 | <1% | 2,723 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,030 | $4K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 306 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 48 | $4K |
| 83605 | <1% | 1,866 | $4K | |
| 87070 | <1% | 967 | $3K | |
| 80143 | <1% | 1,125 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 40 | $3K |
| 86003 | <1% | 12 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,818 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,071 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,042 | $3K |
| 73030 | <1% | 177 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,252 | $3K |
| 87077 | <1% | 1,274 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,548 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 140 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 152 | $2K |
| 85379 | <1% | 578 | $2K | |
| 80061 | Lipid panel | <1% | 438 | $2K |
| 73610 | <1% | 120 | $2K | |
| 71250 | <1% | 60 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 31 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 733 | $2K |
| 80069 | <1% | 1,976 | $2K | |
| 87186 | <1% | 1,139 | $2K | |
| 96450 | <1% | 12 | $1K | |
| 82785 | <1% | 24 | $1K | |
| 85652 | <1% | 175 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 414 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 11,850 | $1K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 13 | $1K |
| 85007 | <1% | 109 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 217 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 740 | $1K |
| 73560 | <1% | 62 | $953.45 | |
| 82570 | <1% | 1,776 | $901.77 | |
| 93356 | <1% | 694 | $872.23 | |
| 82550 | <1% | 726 | $869.63 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 178 | $801.87 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,507 | $798.17 |
| 88108 | <1% | 12 | $763.92 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,295 | $702.70 |
| 84156 | <1% | 1,668 | $686.43 | |
| 93971 | <1% | 125 | $658.18 | |
| 76820 | <1% | 29 | $626.92 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $570.06 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 84 | $567.19 |
| 89051 | <1% | 37 | $549.19 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,114 | $548.35 |
| 83789 | <1% | 13 | $514.70 | |
| 94644 | <1% | 24 | $512.97 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 496 | $470.23 |
| 96376 | <1% | 390 | $418.73 | |
| 73130 | <1% | 16 | $385.45 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,546 | $345.88 |
| C1729 | Catheter, drainage | <1% | 181 | $340.27 |
| 82803 | <1% | 75 | $337.08 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 813 | $307.74 |
| 99153 | Mod sedat endo service >5yrs | <1% | 59 | $299.14 |
| 73502 | <1% | 57 | $284.53 | |
| 0097U | <1% | 1,407 | $273.46 | |
| 87205 | <1% | 287 | $265.12 | |
| 0098U | <1% | 635 | $262.18 | |
| 90715 | <1% | 79 | $253.53 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 467 | $240.77 |
| 72131 | <1% | 15 | $213.76 | |
| 84030 | <1% | 13 | $184.43 | |
| A9270 | Non-covered item or service | <1% | 8,368 | $184.06 |
| C1769 | Guide wire | <1% | 658 | $183.62 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $144.73 |
| 88342 | <1% | 40 | $133.39 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 338 | $118.52 |
| 88341 | <1% | 14 | $109.92 | |
| 82728 | <1% | 27 | $99.22 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 249 | $90.78 |
| 76376 | <1% | 38 | $70.91 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13 | $68.81 |
| 73590 | <1% | 17 | $61.48 | |
| 87340 | <1% | 27 | $58.03 | |
| 86665 | <1% | 13 | $56.98 | |
| 97802 | <1% | 143 | $50.19 | |
| 86803 | <1% | 15 | $48.28 | |
| 86787 | <1% | 12 | $40.46 | |
| S5000 | Prescription drug, generic | <1% | 18 | $39.88 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,282 | $35.74 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 12 | $33.33 |
| 86141 | <1% | 51 | $32.93 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 75 | $28.36 |
| J1815 | Injection, insulin, per 5 units | <1% | 187 | $25.33 |
| 82105 | <1% | 12 | $25.26 | |
| 86644 | <1% | 12 | $22.61 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 38 | $18.88 |
| 86706 | <1% | 13 | $16.86 | |
| 84439 | <1% | 13 | $15.16 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 16 | $14.94 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 36 | $14.58 |
| 82010 | <1% | 16 | $13.72 | |
| 82140 | <1% | 14 | $12.24 | |
| 81000 | <1% | 13 | $6.42 | |
| 76819 | Fetal biophysical profile; without non-stress testing | 0% | 13 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| J3490 | Unclassified drugs | 0% | 58 | $0.00 |
| 87420 | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHERRON, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Northern Utah Healthcare Corporation | Salt Lake City, UT | $35.69M |
| Bay Medical, LLC | Chesapeake Beach, MD | $922K |
| Sugar Mill Diagnostic Imaging LLC | Homosassa, FL | $170.68 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.